MA29352B1 - Composes aromatiques fusionnes ayant une activite anti-diabetique - Google Patents

Composes aromatiques fusionnes ayant une activite anti-diabetique

Info

Publication number
MA29352B1
MA29352B1 MA30253A MA30253A MA29352B1 MA 29352 B1 MA29352 B1 MA 29352B1 MA 30253 A MA30253 A MA 30253A MA 30253 A MA30253 A MA 30253A MA 29352 B1 MA29352 B1 MA 29352B1
Authority
MA
Morocco
Prior art keywords
aromatic compounds
fused aromatic
diabetic activity
diabetes
type
Prior art date
Application number
MA30253A
Other languages
English (en)
Inventor
Harold B Wood
Peter T Meinke
Guo Q Shi
Yong Zhang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA29352B1 publication Critical patent/MA29352B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Les composés aromatiques condensés de formule I sont des agonistes ou agonistes partiels de PPAR gamma et sont utiles dans le traitement ou le contrôle du diabète type II, y compris les hyperglycémie, dyslipidémie, hyperlipidémie, hypercholestérolémie, hypertriglycéridémie, et obésité qui sont souvent associées au diabète type 2.
MA30253A 2005-03-04 2007-09-27 Composes aromatiques fusionnes ayant une activite anti-diabetique MA29352B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65866105P 2005-03-04 2005-03-04

Publications (1)

Publication Number Publication Date
MA29352B1 true MA29352B1 (fr) 2008-03-03

Family

ID=36615702

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30253A MA29352B1 (fr) 2005-03-04 2007-09-27 Composes aromatiques fusionnes ayant une activite anti-diabetique

Country Status (18)

Country Link
US (1) US7834036B2 (fr)
EP (1) EP1861382B1 (fr)
JP (1) JP4638512B2 (fr)
KR (1) KR20070110324A (fr)
CN (2) CN102584754B (fr)
AU (1) AU2006220809B2 (fr)
BR (1) BRPI0609352A2 (fr)
CA (1) CA2598725C (fr)
CR (1) CR9401A (fr)
ES (1) ES2393793T3 (fr)
IL (1) IL185394A0 (fr)
MA (1) MA29352B1 (fr)
MX (1) MX2007010745A (fr)
NI (1) NI200700200A (fr)
NO (1) NO20075000L (fr)
RU (1) RU2007136784A (fr)
WO (1) WO2006096564A1 (fr)
ZA (1) ZA200706394B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1993543A2 (fr) * 2006-03-03 2008-11-26 Merck & Co., Inc. Nouvelles formes cristallines de composés antidiabétiques
US8258161B2 (en) 2007-03-02 2012-09-04 Merck Sharp & Dohme Corp. Crystalline salt form of an antidiabetic compound
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2155187B1 (fr) * 2007-05-07 2016-05-25 Merck Sharp & Dohme Corp. Procédé de traitement à l'aide de composés aromatiques fusionnés ayant une activité anti-diabétique
WO2010080976A1 (fr) * 2009-01-09 2010-07-15 Sdg, Inc. (An Ohio Corporation) Insulinothérapies pour le traitement du diabète, des maladies associées au diabète et/ou des maladies ou pathologies autres que le diabète ou que les maladies associées au diabète
WO2014134776A1 (fr) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
CN104725219B (zh) * 2015-02-11 2017-08-08 华中农业大学 S‑2‑(4‑甲氧基苯氧基)丙酸钠的制备方法
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
AU2019209470A1 (en) 2018-01-16 2020-08-13 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CA3088529A1 (fr) 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
EP3873462A4 (fr) 2018-11-01 2022-08-03 Syros Pharmaceuticals, Inc. Méthodes de traitement du cancer chez des patients identifiés par biomarqueurs avec des inhibiteurs non covalents de la kinase cycline-dépendante 7 (cdk7)
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386750A1 (fr) 1999-10-22 2001-05-03 Merck & Co. Inc. Medicaments destines au traitement de l'obesite
JP2003523336A (ja) * 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
JP2001354671A (ja) * 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
CA2415742A1 (fr) 2000-07-25 2002-01-31 Merck & Co., Inc. Indoles n-substitues utiles pour le traitement du diabete
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
EP1366012A4 (fr) * 2001-02-09 2005-11-02 Merck & Co Inc Acides 2-aryloxy-2-arylalcano ques utilis s pour le traitement du diab tes et des troubles lipidiques
JP4542757B2 (ja) * 2002-08-08 2010-09-15 武田薬品工業株式会社 縮合複素環化合物
TW200404060A (en) * 2002-08-08 2004-03-16 Takeda Chemical Industries Ltd Fused heterocyclic compounds
CA2495943C (fr) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles a activite antidiabetique
WO2004019869A2 (fr) * 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles presentant un effet antidiabetique
ATE488236T1 (de) 2004-09-16 2010-12-15 Merck Sharp & Dohme Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen

Also Published As

Publication number Publication date
JP4638512B2 (ja) 2011-02-23
CN102584754B (zh) 2016-02-03
CA2598725C (fr) 2010-10-26
CN102584754A (zh) 2012-07-18
ES2393793T3 (es) 2012-12-28
ZA200706394B (en) 2008-09-25
US20080194586A1 (en) 2008-08-14
CA2598725A1 (fr) 2006-09-14
CR9401A (es) 2008-02-21
AU2006220809B2 (en) 2009-06-11
NO20075000L (no) 2007-11-30
WO2006096564A1 (fr) 2006-09-14
RU2007136784A (ru) 2009-04-10
EP1861382B1 (fr) 2012-10-10
JP2008531729A (ja) 2008-08-14
IL185394A0 (en) 2008-02-09
BRPI0609352A2 (pt) 2011-10-18
CN101128441A (zh) 2008-02-20
NI200700200A (es) 2008-02-29
AU2006220809A1 (en) 2006-09-14
MX2007010745A (es) 2007-09-12
EP1861382A1 (fr) 2007-12-05
KR20070110324A (ko) 2007-11-16
US7834036B2 (en) 2010-11-16

Similar Documents

Publication Publication Date Title
NO20075000L (no) Kondenserte aromatiske forbindelser med anti-diabetisk aktivitet
EP1305285A4 (fr) Indoles n-substitues utiles pour le traitement du diabete
MA35864B1 (fr) Analogues du glucagon
WO2008036678A3 (fr) Modulation induite par ppar de la neurogenèse
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
EP1855649A4 (fr) Methode de traitement de l'atherosclerose, de dyslipidemies et de troubles lies
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
BRPI0511527A (pt) compostos e composições como moduladores de ppar
WO2007084711A3 (fr) Utilisation de protéines gr2 pour modifier des matériaux cellulosiques et pour améliorer la modification enzymatique et chimique de cellulose
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
DE602006020246D1 (de) Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kb-aktivität und deren verwendung
MA32158B1 (fr) Thiazolyldihydroindazoles
ATE363475T1 (de) Antidiabetische oxazolidindione und thiazolidindione
WO2006014262A3 (fr) Indoles a activite antidiabetique
DK2022786T3 (da) Middel mod mund- og klovsyge-virus til dyr, der hører til familien suidae eller får, og fremgangsmåde til forebyggelse eller behandling af mund- og klovsyge hos dyr, der hører til familien suidae eller får
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
ATE478056T1 (de) Oxazol- und thiazol-verbindungen als ppar- modulatoren
EP3929366A4 (fr) Commutateur de robinet de vidange doté d'une structure d'embrayage, et robinet de vidange
MA32012B1 (fr) Octahydroquinolizines destinees au traitement du diabete
WO2007018956A3 (fr) Oxazolidinediones et thiazolidinediones antidiabetiques